Pelareorep combined with atezolizumab and chemotherapy demonstrates encouraging results as first-line treatment in advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients – Interim results from the GOBLET study

Arnold, Dirk et al, Previously presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting; November 8-12, 2022